Severe Pediatric Onset IBD May See New Therapy Via Three-Part Venture

Severe Pediatric Onset IBD May See New Therapy Via Three-Part Venture
Medgenics recently announced a partnership with Kyowa Hakko Kirin to develop and commercialize the company's first-in-class anti-LIGHT monoclonal antibody for severe pediatric onset inflammatory bowel disease (IBD). Plans are in the works to begin signal testing in children with the condition. Testing will occur through a joint venture that includes Dr. Robert Baldassano, Director of the Center for Pediatric IBD at The Children's Hospital of Philadelphia (CHOP). Children with IBD and other autoimmune related  diseases can carry mutations that lead to function loss of the immune protein decoy receptor 3 (DcR3). The molecule inhibits inflammation by binding to pro-inflammatory proteins, like LIGHT (ligand for herpesvirus entry mediator); a major contributor to chronic IBD and other related autoimmune diseases. The anti-LIGHT works as a substitute for DcR3. The potential therapeutic agent for children with IBD helps control inflammation.  "IBD is a distinct and severe genetic disease in children, with very limited treatment options available. I am pleased to see Medgenics and Kyowa Hakko Kirin come together to advance the development of this program," Baldassano said in a press release. The companies maintain that the anti-LIGHT monoclonal antibody can become a valuable first-in-class biological therapy for severe pediatric onset IBD, especially in patients who fail to respond
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *